期刊文献+

血清可溶性CXCL16在子痫前期患者中的表达变化及其临床意义

Changes of Serum Soluble CXCL16 Expression in Patients with Preeclampsia and its Clinical Significance
下载PDF
导出
摘要 目的探究子痫前期患者血清可溶性CXCL16的表达变化及其与肝脏或肾脏损伤的关系。方法选取2017年3月-2019年3月于河南大学附属郑州颐和医院明确诊断的子痫前期患者58例作为研究组,选取同期健康体检妊娠孕妇30例为对照组,两组间年龄、孕周及BMI等一般资料比较差异无统计学意义。依据疾病严重程度将研究组分为轻度子痫前期组(30例)和重度子痫前期组(28例)。酶联免疫吸附试验测定血清CXCL16的浓度,比较各组间CXCL16和临床资料间的差异。结果子痫前期患者收缩压、舒张压、丙氨酸氨基转移酶(ALT)、天门冬酸氨基转移酶(AST)以及血肌酐浓度均显著高于对照组,而血小板计数(PLT)则显著低于对照组。与对照组相比,CXCL16浓度亦显著升高,差异有统计学意义(P<0.05)。此外,重度子痫前期患者血清CXCL16浓度显著高于轻度子痫前期患者和对照组。相关性分析显示CXCL16水平与ALT、AST和肌酐均呈显著正相关性,且ROC曲线下面积高达0.895 1,最佳诊断界值为0.85 pg/ml。结论血清可溶性CXCL16在子痫前期患者中表达上调,并与疾病严重程度及肝肾功能密切相关,且具有良好的诊断价值。 Objective To investigate the expression of serum soluble CXCL16 in patients with preeclampsia and its relationship with liver or kidney injury. Methods 58 cases of preeclampsia were selected as the study group, and 30 cases of pregnant women who underwent health examination during the same period were selected as the control group. There was no significant difference in age, gestational age and BMI between the two groups. According to the severity of the disease, the study group were divided into mild preeclampsia group(30 cases) and severe preeclampsia group(28 cases). Enzyme-linked immunosorbent assay(ELISA) was used to determine the concentration of CXCL16 in serum, and the differences of CXCL16 and clinical data between groups were compared. Results Systolic blood pressure, diastolic blood pressure, ALT, AST and serum creatinine concentration in preeclampsia patients were significantly higher than those in control group, while PLT was significantly lower than that in control group. Compared with the control group, the concentration of CXCL16 also increased significantly(P<0.05). In addition, serum CXCL17 concentration in severe preeclampsia patients was significantly higher than those in mild preeclampsia patients and control group. The correlation analysis showed that the level of CXCL16 was positively correlated with ALT, AST and creatinine, and the area under ROC curve was as high as 0.895 1. The optimal diagnostic threshold was 0.85 pg/ml. Conclusion Serum soluble CXCL16 is up-regulated in patients with preeclampsia, which is closely related to the severity of the disease and liver and kidney function, and has good diagnostic value.
作者 陈瑞 CHEN Rui(Laboratory Department,Zhengzhou Yihe Hospital Affiliated to Henan University,Zhengzhou,450047,China)
出处 《黑龙江医学》 2020年第3期366-368,共3页 Heilongjiang Medical Journal
关键词 子痫前期 CXC趋化因子配体16 诊断 Preeclampsia CXC chemokine ligand 16 Diagnosis
  • 相关文献

参考文献4

二级参考文献17

  • 1Macfarlane GT, Blackett KL, Nakayama T, et al. The gut microbiota in inflammatory bowel disease[J]. Curr Pharm Des, 2009, 15(13) :1 528-1 536.
  • 2Elson CO, Cong Y, McCracken VJ, et al. Experimen- tal models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota[J]. Immunol Rev, 2005, 206: 260-276.
  • 3Kleessen B, Kroesen AJ, Buhr HJ, et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls[J]. Scand J Gastroen- terol, 2002, 37(9): 1 034-1 041.
  • 4Bouma G, Strober W. The immunological and genetic basisof inflammatory bowel disease[J]. Nat Rev Immu- nol, 2003, 3(7) 521-533.
  • 5Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease[J]. Nature, 2007, 448 (7 152) :427-434.
  • 6Chandrasekar B, Mummidi S, Valente AJ, et al. The pro-atherogenic cytokine interleukin-18 induces CX- CL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis {actor receptor-associated factor 6, c- Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-ter- minal kinase, and activator protein-1 signaling [J]. J Biol Chem, 2005, 280(28): 26 263-26 277.
  • 7Schoepfer AM, Beglinger C, Straumann A, et al. Ul- cerative colitis: Correlation of the Rachmilewitz endo- scopic activity index with fecal calprotectin, clinical ac- tivity, C-reactive protein, and blood leukocytes[J]. In- flamm Bowel Dis, 2009, 15(12):1 851-1 858.
  • 8Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications [J]. Gut, 2006, 55(6) :749-753.
  • 9Sartor RB. Therapeutic manipulation of the enteric mi- croflora in inflammatory bowel diseases: antibiotics,probiotics, and prebiotics[J]. Gastroenterology, 2004, 126(6): 1 620-1 633.
  • 10Franchimont D, Vermeire S, EI H, et al. Deficient host-bacteria interactions in inflammatory bowel dis- ease? The toll-like receptor (TLR)-4 Asp299gly poly- morphism is associated with Crohn's disease and ulcera- tive colitis[J]. Gut, 2004, 53(7): 987-992.

共引文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部